带状疱疹疫苗卖不动，疫苗企业“打骨折”

Core Viewpoint - The price war for shingles vaccines in China has intensified, with significant price reductions announced by domestic manufacturers, particularly Baike Biological, which has cut its vaccine price from 1375 yuan to 464 yuan, a reduction of approximately 66% [3][4]. Group 1: Vaccine Pricing and Market Dynamics - Baike Biological's shingles vaccine, approved for domestic use in January 2023, initially boosted the company's performance, but sales have since declined, leading to a net loss of 158 million yuan in Q3 2025 [8]. - The imported shingles vaccine from GlaxoSmithKline is also facing pricing pressures, with promotional offers reducing the total cost of vaccination to around 1600 yuan, effectively a 50% discount [6][9]. - The competition between domestic and imported vaccines is expected to continue, as both seek to increase public vaccination rates amid declining consumer interest [9]. Group 2: Market Potential and Challenges - The shingles vaccine market in China is viewed as having significant potential due to the aging population, which increases the risk of shingles infections [7]. - Despite the potential, convincing the target demographic of older adults to receive the vaccine remains a challenge, as evidenced by the declining sales figures for both domestic and imported vaccines [8][9]. - Public health experts emphasize the importance of vaccination in preventing shingles and its complications, highlighting the need for increased awareness and education among the elderly [7].